John Palmer, DO
Endocrinology, Diabetes & Metabolism · Rapid City, SDNPI 1063510691
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $390,815 of the $418,585 with a category attached, or 93.4%. 22 manufacturers reported payments, led by Novo Nordisk at 35.1% of the total. Reporting peaked in 2019 at $121,942 and has fallen 96.9% since, to $3,757 in 2025. Among endocrinology, diabetes & metabolism clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 811 payments — averaging $516.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$147K
- Lilly USA, LLC$91K
- Sanofi-aventis U.S. LLC$64K
- AstraZeneca$36K
- Dexcom, Inc.$27K
- Boehringer Ingelheim$24K
- plus $29K from 16 others
What the payments were for
- Consulting fees$2,9251%
- Speaking & faculty fees$390,81593%
- Travel & lodging$13,4233%
- Food & beverage$10,9083%
- Education$5140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 282 | $146,986 |
| Lilly USA, LLC | 185 | $91,469 |
| Sanofi-aventis U.S. LLC | 80 | $64,169 |
| AstraZeneca | 46 | $36,334 |
| Dexcom, Inc. | 41 | $26,714 |
| Boehringer Ingelheim | 71 | $24,143 |
| Johnson & Johnson | 33 | $20,511 |
| Bayer | 6 | $5,221 |
| Medtronic(2 entities) | 44 | $2,274 |
| Abbott | 3 | $389 |
| Amgen | 4 | $80 |
| Novartis | 4 | $68 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Nevro Corp. | 1 | $38 |
| Pfizer | 2 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| BD | 1 | $25 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $11 |
| Actelion Pharmaceuticals US, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$71,579
- SOLIQUA 100/33$51,407
- Ozempic$50,825
- MOUNJARO$43,351
- JARDIANCE$38,651
- FARXIGA$36,086
- TRULICITY$28,813
- INVOKANA$20,320
- DEXCOM G7 GSS (161)$14,171
- Tresiba$13,511
- TOUJEO$12,352
- Kerendia$5,169
- DEXCOM G6 TRANSMITTER$5,007
- Xultophy 100/3.6$3,655
- DEXCOM CGM$3,500
- DEXCOM G6 CGM SYSTEM$3,400
- DEXCOM STELO GLUCOSE BIOSENSOR$2,681
- MINIMED 780G$837
- FreeStyle Lite system$360
- Minimed 630G$140
How this compares
$418,585 in reported general payments places this provider in the 95th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.
See all endocrinology, diabetes & metabolism providers in South Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 26 | $2,248,698 |
| OzempicSemaglutide | 605 | $810,074 |
| JardianceEmpagliflozin | 392 | $450,654 |
| MounjaroTirzepatide | 264 | $377,868 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 165 | $237,937 |
| TrulicityDulaglutide | 106 | $142,310 |
| Tresiba Flextouch U-100Insulin Degludec | 236 | $141,213 |
| Tresiba Flextouch U-200Insulin Degludec | 117 | $116,573 |
| FarxigaDapagliflozin Propanediol | 109 | $113,679 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 111 | $108,664 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 137 | $100,061 |
| JanuviaSitagliptin Phosphate | 78 | $74,979 |
| Novolog FlexpenInsulin Aspart | 249 | $74,503 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $74,178 |
| RybelsusSemaglutide | 24 | $51,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $36,334 | $2,362,378135 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Xultophy 100-3.6 | $146,986 | $941,518690 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $91,469 | $531,787416 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $24,143 | $477,588439 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $64,169 | $237,937165 claims |
| Johnson & JohnsonInvokana | $20,511 | $22,13222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.
Other endocrinology, diabetes & metabolism in Rapid City
- Sonalika KhachikianRapid City$365K
- Melanie RayanRapid City$451
- Richard CrawfordSioux Falls$126K
- Brandon AllardSioux Falls$3K
- Randall FennerSioux Falls$2K
- Marie Angelica DiazSioux Falls$2K
- Hassan MehmoodSioux Falls$1K
- Lorayne ChuaSioux Falls$1K
- Marcio GriebelerSioux Falls$1K
- Anthony SallarSioux Falls$921
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.